Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.
Riopel M, Vassallo M, Ehinger E, Pattison J, Bowden K, Winkels H, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Larson CJ, Ley K, Cabrales P, Witztum JL, Olefsky JM, Lee YS. Riopel M, et al. Among authors: plonowski a. Mol Metab. 2019 Feb;20:89-101. doi: 10.1016/j.molmet.2018.11.011. Epub 2018 Dec 2. Mol Metab. 2019. PMID: 30553772 Free PMC article.
Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function.
Riopel M, Seo JB, Bandyopadhyay GK, Li P, Wollam J, Chung H, Jung SR, Murphy A, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Koh DS, Larson CJ, Olefsky JM, Lee YS. Riopel M, et al. Among authors: plonowski a. J Clin Invest. 2018 Apr 2;128(4):1458-1470. doi: 10.1172/JCI94330. Epub 2018 Mar 5. J Clin Invest. 2018. PMID: 29504946 Free PMC article.
Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.
Farrell PJ, Zopf CJ, Huang HJ, Balakrishna D, Holub C, Bilakovics J, Fanjul A, Matuszkiewicz J, Plonowski A, Rolzin P, Banerjee U, Ermolieff J, Cheruvallath ZS, McBride C, Bartkowski D, Mazur C, Pachori A, Larson CJ. Farrell PJ, et al. Among authors: plonowski a. J Pharmacol Exp Ther. 2019 Nov;371(2):299-308. doi: 10.1124/jpet.119.259028. Epub 2019 Sep 19. J Pharmacol Exp Ther. 2019. PMID: 31537613
Time-dependent inhibition of PHD2.
Tcholakov I, Grimshaw CE, Shi L, Kiryanov A, Murphy ST, Larson CJ, Plonowski A, Ermolieff J. Tcholakov I, et al. Among authors: plonowski a. Biosci Rep. 2017 Jun 30;37(3):BSR20170275. doi: 10.1042/BSR20170275. Print 2017 Jun 30. Biosci Rep. 2017. PMID: 28592559 Free PMC article.
Discovery and characterization of an inhibitor of glucosylceramide synthase.
Richards S, Larson CJ, Koltun ES, Hanel A, Chan V, Nachtigall J, Harrison A, Aay N, Du H, Arcalas A, Galan A, Zhang J, Zhang W, Won KA, Tam D, Qian F, Wang T, Finn P, Ogilvie K, Rosen J, Aoyama R, Plonowski A, Cancilla B, Bentzien F, Yakes M, Mohan R, Lamb P, Nuss J, Kearney P. Richards S, et al. Among authors: plonowski a. J Med Chem. 2012 May 10;55(9):4322-35. doi: 10.1021/jm300122u. Epub 2012 Apr 19. J Med Chem. 2012. PMID: 22497444
Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.
Kick E, Martin R, Xie Y, Flatt B, Schweiger E, Wang TL, Busch B, Nyman M, Gu XH, Yan G, Wagner B, Nanao M, Nguyen L, Stout T, Plonowski A, Schulman I, Ostrowski J, Kirchgessner T, Wexler R, Mohan R. Kick E, et al. Among authors: plonowski a. Bioorg Med Chem Lett. 2015 Jan 15;25(2):372-7. doi: 10.1016/j.bmcl.2014.11.029. Epub 2014 Nov 15. Bioorg Med Chem Lett. 2015. PMID: 25435151
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
Foster P, Yamaguchi K, Hsu PP, Qian F, Du X, Wu J, Won KA, Yu P, Jaeger CT, Zhang W, Marlowe CK, Keast P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Engell K, Bentzien F, Lam ST, Dale S, Yturralde O, Matthews DJ, Lamb P, Laird AD. Foster P, et al. Among authors: plonowski a. Mol Cancer Ther. 2015 Apr;14(4):931-40. doi: 10.1158/1535-7163.MCT-14-0833. Epub 2015 Jan 30. Mol Cancer Ther. 2015. PMID: 25637314
Discovery of Highly Potent Liver X Receptor β Agonists.
Kick EK, Busch BB, Martin R, Stevens WC, Bollu V, Xie Y, Boren BC, Nyman MC, Nanao MH, Nguyen L, Plonowski A, Schulman IG, Yan G, Zhang H, Hou X, Valente MN, Narayanan R, Behnia K, Rodrigues AD, Brock B, Smalley J, Cantor GH, Lupisella J, Sleph P, Grimm D, Ostrowski J, Wexler RR, Kirchgessner T, Mohan R. Kick EK, et al. Among authors: plonowski a. ACS Med Chem Lett. 2016 Oct 23;7(12):1207-1212. doi: 10.1021/acsmedchemlett.6b00234. eCollection 2016 Dec 8. ACS Med Chem Lett. 2016. PMID: 27994765 Free PMC article.
48 results